GoodRx Holdings (GDRX) Share-based Compensation (2019 - 2026)

GoodRx Holdings has disclosed Share-based Compensation across 8 years of filings, most recently posting $16.6 million for Q2 2026.

• In Q2 2026, Share-based Compensation fell 22.52% year-over-year to $16.6 million; the TTM figure through Jun 2026 stood at $69.1 million (down 21.37% YoY), while the FY2025 annual figure was $76.6 million, down 22.62% from the prior year.
• Share-based Compensation came in at $16.6 million for Q2 2026 at GoodRx Holdings, up from $16.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $204.6 million in Q3 2022 to a low of $16.5 million in Q1 2026.
• Average Share-based Compensation over 5 years is $42.9 million, with a median of $25.3 million recorded in 2023.
• Year-over-year, Share-based Compensation jumped 760.71% in 2022 and tumbled 90.8% in 2023.
• Over 5 years, Share-based Compensation stood at $29.4 million in 2022, then decreased by 2.16% to $28.8 million in 2023, then dropped by 27.17% to $21.0 million in 2024, then declined by 14.5% to $17.9 million in 2025, then slipped by 7.4% to $16.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $16.6 million in Q2 2026, $16.5 million in Q1 2026, and $17.9 million in Q4 2025.